Relypsa (RLYP) Reports Q4 Loss of $0.80/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Relypsa (RLYP) PT Bumped to $64 at Wedbush
March 12, 2015 12:24 PM EDTWedbush analyst Liana Moussatos reiterated an Outperform rating and bumped her price target on Relypsa, Inc. (NASDAQ: RLYP) to $64.00 (from $63.00) following in-line Q4.
As expected the company reported no revenue for Q4. With the addition of the Q1 2015 financing activities, Relypsa has... More
Oppenheimer Lists 14 More Reasons to Own Relypsa (RLYP)
March 9, 2015 8:56 AM EDTOppenheimer analyst Yigal Nochomovitz was out pounding the table on Relypsa, Inc. (NASDAQ: RLYP), listing 14 more reasons to own the stock. The firm maintained an Outperform rating and price target of $60.00.
Nochomovitz commented, "The debate surrounding Patiromer vs. competitor ZS-9's safety/efficacy profiles has intensified in recent weeks as investors hone in on how Relypsa and ZS Pharma may take share in the novel market for chronic control of high potassium in CKD/ HF. Fundamentally, we see opportunities for multiple winners given a large untapped market (~3+ MM... More
